Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
在病毒学抑制的 HIV 感染儿童和青少年中，每日一次整合酶抑制剂联合达芦那韦增强治疗方案（无需使用核苷/核苷酸类逆转录酶抑制剂）不劣于标准治疗方案——随机 SMILE Penta-17-ANRS 152 临床试验第 48 周结果
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102025
Compagnucci, Alexandra; Chan, Man K; Saïdi, Yacine; Cressey, Tim R; Bamford, Alasdair; Riault, Yoann; Coelho, Alexandra; Nolan, Aoife; Chalermpantmetagul, Suwalai; Morkunaite, Gabija; Amuge, Pauline; Musiime, Victor; Violari, Avy; Cotton, Mark; Kekitiinwa, Adeodata R; Kaudha, Elizabeth; Groenewald, Marisa; Liberty, Afaaf A; Kanjanavanit, Suparat; Volokha, Alla; Bologna, Rosa; Pavia Ruz, Noris; Prieto Tato, Luis; Paioni, Paolo; Marques, Laura; Reliquet, Véronique; Niehues, Tim; Welch, Steven B; Ford, Deborah; Giaquinto, Carlo; Gibb, Diana M; Babiker, Abdel; Ramos Amador, Jose Tomas
